Category: News
BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)
Bergen, Norway, 6 March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read MoreBERGENBIO ANNOUNCES START OF PHASE 1B TRIAL OF ANTI-AXL ANTIBODY TILVESTAMAB (BGB149)
Bergen, Norway, 5 March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read MoreBERGENBIO CLOSES RECRUITMENT INTO TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Bergen, Norway, 4th March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read MoreBERGENBIO ASA: ANNUAL REPORT 2020
Bergen, Norway, 25 February 2021 – Reference is made to the notice on 23 February 2021 and the…
Read MoreRadium Podcast interview with BerGenBio CEO Richard Godfrey, hosted by RADFORSK
Bergen, Norway, 17 February 2021 - In this Radium podcast interview with RADFORSK, BerGenBio CEO Richard Godfrey…
Read MoreBERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2020
Bergen, Norway, 10 February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for…
Read More
